Orphazyme expects to lay off 100 employees this year

At the end of July, Orphazyme completed its restructuring program, and according to the biotech company, it expects to have around 70 full-time employees at the end of the year. At the end of the first half-year, 180 people were employed.

Photo: Orphazyme/PR

It is no secret that Orphazyme has been forced to cut down its number of staff considerably after the FDA rejected the biotech company's key candidate arimoclomal as a treatment for metabolic disease Niemann-Pick type C, NPC.

The company has previously announced a reduction of its global workforce equating to around two-thirds of the workforce, and the publication of the half-year report on Tuesday revealed more details of the reductions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs